Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOSEASONIQUE vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Treatment of moderate acne vulgaris in women at least 14 years old who have achieved menarche and desire an oral contraceptive,Treatment of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is 12-15 hours, supporting once-daily dosing.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Ethinyl estradiol: primarily metabolized by CYP3A4, undergoes conjugation and enterohepatic recirculation. Drospirenone: extensively metabolized by CYP3A4, with minor involvement of CYP1A1 and CYP2C9; forms two major metabolites (dihydrodrospirenone and drospirenone sulfate) that are not pharmacologically active.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal: ~50% as metabolites; fecal: ~30% as metabolites; biliary: minor.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Ethinyl estradiol: ~97% bound to albumin; progestin: ~99% bound to SHBG and albumin.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Ethinyl estradiol: 4-5 L/kg; progestin: 2-3 L/kg; indicates extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral: ~40-60% for ethinyl estradiol due to first-pass metabolism; progestin: >80%.
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in Child-Pugh Class B or C hepatic impairment; no specific dose adjustment defined for mild impairment but use with caution.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and efficacy established in females of reproductive age; postmenarche use as per adult dosing. Not indicated before menarche.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in postmenopausal women; no geriatric-specific dosing.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, especially in women over 35 years, and with the number of cigarettes smoked. Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Hepatic disease (acute hepatitis, benign/malignant liver tumors),Hypertension (contraindicated if uncontrolled),Gallbladder disease,Carbohydrate/lipid metabolism effects,Headache (including migraine with focal aura),Uterine bleeding irregularities,Depression,Fluid retention,Ocular lesions (retinal thrombosis),Cervical cancer screening,Hereditary angioedema,Chloasma,Drug interactions (especially CYP3A4 inducers),Laboratory test interference (sex hormone-binding globulin, thyroid-binding globulin)
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer,Endometrial cancer or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Uncontrolled hypertension (BP ≥ 160/100 mm Hg),Diabetes with vascular involvement,Headache with focal neurological symptoms (migraine with aura) in women over 35,Major surgery with prolonged immobilization,Heavy smoking (≥15 cigarettes/day) in women over 35,Hypersensitivity to any component of the drug
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No specific dietary restrictions. Grapefruit may slightly increase ethinyl estradiol levels; consistent intake is advised. Alcohol in moderation does not affect efficacy. Always take with or without food consistently.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects and limb reduction. Second and third trimester exposure may result in fetal harm including masculinization of female genitalia (progestin effect) and possible hepatic adenoma. Discontinue immediately if pregnancy occurs.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in breast milk. Estrogens may reduce milk quantity and quality. M/P ratio not established. Use not recommended during breastfeeding; alternative contraception advised.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustment applicable; drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
LOSEASONIQUE (ethinyl estradiol/levonorgestrel) is a combined oral contraceptive with a shortened hormone-free interval (2 days of placebo vs. typical 7 days) to reduce withdrawal bleeding duration and frequency. Counsel patients that spotting/breakthrough bleeding may occur more commonly in the first few cycles. It does not protect against STIs. Consider alternative contraception in patients with contraindications like smoking >35, hypertension, migraine with aura, or history of thromboembolism.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time, even during placebo days, to maintain contraceptive efficacy.,If a dose is missed, follow the package instructions; missed pills increase pregnancy risk.,Spotting or breakthrough bleeding is common in the first 3 months and usually resolves.,Do not smoke while taking this medication, especially if over 35 years old, due to increased risk of blood clots.,This medication does not protect against HIV or other sexually transmitted infections.,Use back-up contraception (e.g., condoms) if you have vomiting or severe diarrhea for more than 48 hours.,Report any signs of blood clots: sudden chest pain, shortness of breath, leg swelling/pain, or severe headache.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOSEASONIQUE vs ALTAVERA, answered by our medical review team.
LOSEASONIQUE is a Oral contraceptive that works by Combination of ethinyl estradiol and drospirenone; ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOSEASONIQUE and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOSEASONIQUE is: One tablet (ethinyl estradiol 0.02 mg/levonorgestrel 0.1 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOSEASONIQUE and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOSEASONIQUE is classified as Category C. Category X. Estrogen-progestin combinations are contraindicated in pregnancy. First trimester exposure associated with risk of congenital anomalies, particularly cardiac defects an. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.